How Sol-Gel is Responding to Covid-19


A clinical-stage dermatology company focused on identifying, developing, and commercializing topical drug products for the treatment of skin diseases.

We have leveraged our proprietary technology platform, which utilizes a microencapsulation process, to develop two innovative topical formulations, TWYNEO® (benzoyl peroxide and tretinoin) Cream, 3%/0.1% and EPSOLAY® (benzoyl peroxide) Cream, 5%. These formulations are currently under investigation for the treatment of acne and papulopustular rosacea, respectively.

The pipeline also includes SGT-210—an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, which is being investigated for the treatment of palmoplantar keratoderma—and preclinical assets SGT-310 (tapinorof) and SGT-510 (roflumilast) for the treatment of psoriasis and other dermatological indications.

What Sets Sol-Gel Apart

A diverse, late-stage branded product pipeline using proprietary silica-based drug delivery technology. Extensive knowledge of the dermatology market has been instrumental in establishing a pipeline of branded product candidates. Our innovative drug delivery technology platform has been essential in their development. Further exploration is underway to determine how the technology platform can continue to develop additional products that advance current in-market treatments across multiple skin diseases.

Following the FDA 505(b)(2) pathway for the current branded product pipeline. Twyneo and Epsolay are being submitted under the FDA 505(b)(2) approval pathway, which permits us to rely, in part, upon the FDA’s previous findings of safety and efficacy of an approved product.

A comprehensive and broad intellectual property portfolio. We maintain exclusive, worldwide commercial rights for all of our branded product candidates. If patents are issued, our branded product candidates Twyneo and Epsolay will have patent coverage until 2030, and 2032, respectively.

An experienced leadership team with a proven track record. The leadership team has extensive experience in the development and commercialization of dermatology drug products and is well-positioned to ensure a successful process.

The safety and efficacy of investigational products have not been established.